Big Pharma Sharma | Substack

Last Week Tonight in BioPharma, Week of June 15, 2026

Abbvie + Apogee, Neumora strikes out, Jazz bets on Abcellera, and the FDA starts to turn the page from the Prasad-Makary era.

Jun 22 • Big Pharma Sharma

Cell Therapy is Making Progress Against Solid Tumors — But is Anyone Noticing?

Three under-the-radar cell therapy readouts from ASCO 2026 and where the near-term commercial future for this class may lie

Jun 18 • Big Pharma Sharma

Last Week Tonight in BioPharma: Week of June 8th, 2026

A major GSK acquisition, Tango puts PRMT5 back on the radar, a record-setting IPO, and much more!

Jun 15 • Big Pharma Sharma

ASCO 2026: Attention might be on the Wrong Drug in Frontline Lung Cancer

Sac-TMT may be unlike other TROP2 ADCs and poses a real threat to the PD-1xVEGF class in 1L NSCLC

Jun 9 • Big Pharma Sharma

Last Week Tonight in BioPharma: Week of June 1st, 2026

RevMed PDAC data, IgAN opportunity, CAR-T for kidney transplant, NewLimit Series C, and much more

Jun 6 • Big Pharma Sharma

Become a BioPharma insider

Big Pharma Sharma

Unvarnished takes on Big Pharma strategy, M&A patterns, and competitive positioning. What CEOs are actually signaling—before Wall Street sees it

About Archive Recommendations Sitemap

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts